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Can a toxin gene NAAT be used to predict
toxin EIA and the severity of Clostridium
difficile infection?
Mark I. Garvey1,2* , Craig W. Bradley1, Martyn A. C. Wilkinson1 and Elisabeth Holden1
Abstract
Background: Diagnosis of C. difficile infection (CDI) is controversial because of the many laboratory methods
available and their lack of ability to distinguish between carriage, mild or severe disease. Here we describe whether
a low C. difficile toxin B nucleic acid amplification test (NAAT) cycle threshold (CT) can predict toxin EIA, CDI severity
and mortality.
Methods: A three-stage algorithm was employed for CDI testing, comprising a screening test for glutamate
dehydrogenase (GDH), followed by a NAAT, then a toxin enzyme immunoassay (EIA). All diarrhoeal samples positive
for GDH and NAAT between 2012 and 2016 were analysed. The performance of the NAAT CT value as a classifier of
toxin EIA outcome was analysed using a ROC curve; patient mortality was compared to CTs and toxin EIA via linear
regression models.
Results: A CT value ≤26 was associated with ≥72% toxin EIA positivity; applying a logistic regression model we
demonstrated an association between low CT values and toxin EIA positivity. A CT value of ≤26 was significantly
associated (p = 0.0262) with increased one month mortality, severe cases of CDI or failure of first line treatment. The
ROC curve probabilities demonstrated a CT cut off value of 26.6.
Discussions: Here we demonstrate that a CT ≤26 indicates more severe CDI and is associated with higher
mortality. Samples with a low CT value are often toxin EIA positive, questioning the need for this additional EIA test.
Conclusions: A CT ≤26 could be used to assess the potential for severity of CDI and guide patient treatment.
Keywords: Clostridium Difficile, NAAT, EIA, Severity, Mortality, C. difficile Infection
Introduction
C. difficile is an anaerobic, spore forming Gram positive
bacillus found in diverse environments that is able to
colonise and proliferate in the human gastrointestinal
tract, especially following changes in the indigenous co-
lonic microbiota after antibiotic use [1, 2]. C. difficile is
one of the most common causes of healthcare associated
infection and is responsible for 15 to 25% of all cases of
antibiotic associated diarrhoea [2–4]. The infection
causes an estimated 3000 deaths every year in the UK
and 15,000–20,000 deaths in the USA, with associated
case-fatality rates of 6–17% [4, 5]. It is associated with
gut overgrowth of C. difficile and the production of toxins
A, B, or both, which cause a range of effects, including gut
mucosal damage, colitis, and pseudomembranous colitis
[2, 4]. The primary mediators of inflammation in C. diffi-
cile infection (CDI) are large clostridial toxins, toxin A
and toxin B. The toxins trigger a complex cascade of host
cellular responses to cause diarrhoea, inflammation and
tissue necrosis — the major symptoms of CDI [2, 4]. It
must be noted a small number of healthy people naturally
carry C. difficile in their large intestine and do not have ill
effects from the infection [1].
Since C. difficile diarrhoea cannot be reliably distin-
guished from other causes of healthcare associated diar-
rhoea on clinical grounds alone, laboratory confirmation
is essential [4, 6–10]. However, the diagnosis of CDI
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remains a contentious issue [4, 8, 9, 11]. For decades,
toxin tests were favoured over culture for diagnosis of
CDI because toxins mediate disease, detection was faster
and this method provided evidence of toxin production
in vivo that typically correlated better with clinical dis-
ease [3, 10, 12, 13]. Molecular tests such as nucleic acid
amplification tests (NAAT) target toxin genes but are
similar to culture in detecting C. difficile bacteria regard-
less of toxin production, making it unclear whether posi-
tive NAAT results reflect clinical disease [4, 12, 14]. A
disadvantage for NAATs is that they detect toxin genes
alone and not toxin production which is thought to be
associated with CDI [15]. The uncertain clinical
significance of positive NAAT results is problematic in
inpatient healthcare facilities where C. difficile
colonization is 5 to 10 times more common than CDI
and non-infectious causes of diarrhoea [4, 12, 15]. A
large multi-centre study in the UK led to a change in the
Department of Health diagnostic guidance, after showing
that an algorithmic approach was optimal for laboratory
diagnosis [4]. Two stage algorithms have been widely
adopted, and consist of; an initial screen using glutamate
dehydrogenase (GDH) enzyme immunoassay (EIA) or
toxin gene NAAT to detect the presence of C. difficile,
followed by a second step which detects faecal toxin
using either EIA or a cell cytotoxin assay [4, 8, 11, 13,
16, 17]. The cell cytotoxin assay is used to detect the
presence of C. difficile toxin by its effect on human
tissue cells grown in culture. This test is considered to
be the ‘gold standard’ for diagnosing CDI, however it
requires technical expertise and takes 24 to 48 h to
produce a result [10].
In the UK, screen positive/toxin negative patients
are usually regarded as being colonized with C. diffi-
cile rather than infected, based on a large multicentre
prospective study showing that only patients with de-
tectable faecal toxin had adverse outcomes [2–4].
However, outside the UK, such patients typically iden-
tified with NAATs as a screening test alone, are often
regarded as having CDI [3, 18]. The role of C. difficile
toxin gene NAAT for CDI diagnosis has largely been
polarised between Europe and the US [3, 19]. Data
from the National Healthcare Safety Network
indicated in 2014 ~44% of US hospitals use NAAT
for CDI diagnosis, whilst in Europe that level was
much lower at 5% [3, 19]. Over diagnosis of CDI in
hospitals using standalone NAAT can lead to un-
necessary treatment causing clinicians to miss the real
underlying diagnosis [3]. The outcome of patients
who are NAAT positive/ toxin EIA negative has been
shown to be indistinguishable from that of NAAT
negative and toxin EIA negative patients (in terms of
diarrhoea and CDI related complications) [3, 15].
Additionally, increased mortality is associated with
the presence of faecal toxin but not with NAAT posi-
tive/ toxin negative sample results [15]. While qualita-
tive results of NAAT have poor positive predictive
value for CDI, could there be an alternative role for
NAATs in CDI diagnosis? [12, 15] Here we aimed to
determine if a low NAAT cycle threshold result can
predict severity of CDI and/or mortality using data
from our institution over the past 5 years.
Materials and methods
Setting
Queen Elizabeth Hospital Birmingham (QEHB), part of
University Hospitals Birmingham (UHB) NHS Foundation
Trust is a tertiary referral National Health Service
teaching hospital in Birmingham, UK that provides clinical
services to over one million patients every year.
C. difficile Testing
In line with national guidance, an algorithmic approach
to identifying CDI is undertaken at QEHB [4, 20, 21]. A
three-stage algorithm is employed. Briefly, any patient
with ≥1 episode of unexplained diarrhoea had their fae-
cal specimen tested for CDI. The CDI testing algorithm
consists of an initial screening step using a Premier
GDH EIA (Meridian Bioscience, Cincinnati, Ohio),
followed by a NAAT (Cepheid, Xpert™ C. difficile, US)
for GDH positive samples only. The premier GDH in-
volved undertaking an enzyme immunoassay looking for
the presence of GDH as previously descrbed [4, 21]. The
Cepheid NAAT is a real-time PCR assay targeting the
toxin genes (B toxin gene and tcdB) [12, 14]. The
Cepheid PCR targets the toxin B gene (tcdB) as it is
independently capable of causing CDI [12, 14]. The cycle
threshold (CT) value of the Cepheid real time PCR de-
scribes the number of cycles needed until DNA amplifi-
cation occurs exponentially in a real-time PCR assay and
they are correlated with the amount of target sequence
in the sample [12]. All samples which were GDH and
NAAT positive have a Premier Toxins A and B EIA
(Meridian Bioscience, Cincinnati, Ohio) which is under-
taken once a week [20, 22]. The Premier Toxins A and B
EIA was undertaken as previously described, with a
sensitivity of 94.7% and specificity 97.3% quoted by the
manufacturers when compared to the reference cyto-
toxin method [4, 21].
Study design and definitions
All diarrhoeal samples (Bristol stool type 5–7) [23] from
patients between Jan 2012 to Dec 2016 at QEHB positive
by GDH and NAAT were included in the study which
equated to 1346 patients.
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CDI episode
At QEHB a CDI episode was defined as the presence of
a positive test result for toxigenic C. difficile by GDH
and NAAT and the presence of unexplained diarrhoea
(≥1 episode of unexplained diarrhoea). Severity of CDI
was based on the Public Health England (PHE) toolkit
for management of C. difficile [20]. A severe C. difficile
case was defined as: WCC >15 × 10 [9] g/dL; acutely ris-
ing blood creatinine (e.g. >50% increase above baseline);
temperature > 38.5 °C; or evidence of severe colitis
(abdominal signs, radiology) [20].
Recurrent CDI and treatment failure
Recurrent CDI was defined as the return of diarrhoea
(≥1 episode of unexplained diarrhoea) within 30 days of
a previous CDI episode and the presence of a positive
test result for toxigenic C. difficile by GDH and NAAT
[20]. Treatment failure was defined as cases where fail-
ure to respond to treatment resulted in a change of
management of the patient [12].
Clinical data collection
Patient data collected at the time of a positive result
included: patient demographics (age, sex), markers for
CDI severity (white cell count, C-reactive protein,
serum creatinine, serum albumin, temperature, stool
frequency) and mortality (one month and 3-month
all-cause mortality). Clinical severity data were ob-
tained from 80 patients with the lowest and 138 pa-
tients with the highest CT values; mortality data was
collected from all 1346 patients in the study.
Statistical analysis
Cepheid NAAT CT values were compared to Premier
Toxins A and B EIA positivity and patient mortality (one
and three month). All analyses including receiver operat-
ing characteristic curve (ROC), Youden’s index, error rates
and univariate logistic regression models were performed
using the hmeasure, plotROC and base packages in the
statistical programming language R [24–26].
ROC curve
The performance of NAAT CT value as a classifier of
toxin EIA positivity was assessed using a ROC curve and
the area under the ROC curve (AUC). The sensitivity
(TPF; True Positive Fraction), specificity, False Positive
Fraction (FPF), Positive Predictive Value (PPV) and
negative predictive value (NPV) of the prediction rule of
low CT values corresponding to EIA positivity were cal-
culated using the hmeasure and plotROC packages in R
[24, 25]. To determine a NAAT CT cut off value, two
commonly-used strategies were used in the study pick-
ing a threshold that minimises the error rate and picking
one that maximises Youden’s index [27, 28].
Linear regression mortality
Logistic regression models were used to assess NAAT
CT values as an explanatory variable for mortality
and EIA toxin positivity. These models were fitted
using R [26].
Results
Samples
Between Jan 01 2012 and Dec 31 2016; 26,931 diarrhoeal
stool samples were tested for CDI at QEHB. Of the
26,931 samples 2807 (10%) were GDH positive, of these
1650 (59%) were NAAT positive. Of the 1650 GDH and
NAAT positives, 754 (46%) were toxin EIA positive
(Fig. 1).
NAAT CT vs EIA
The mean toxin B CT-value of all samples was 27.1
(n = 1650). Low CT values were associated with toxin
EIA positivity (Table 1). A CT value of <26 was asso-
ciated with ≥72% toxin EIA positivity as compared to
a CT value ≥26 where a 23% EIA positivity rate was
observed (Table 1). To test the model of low CT
values corresponding to EIA positivity a ROC curve
was calculated (Fig. 2). The area under the ROC
curve (AUC) was equal to AUC = 0.819 (Table 2). For
our data, we have a minimum error rate of
Fig. 1 Algorithm of CDI testing at QEHB with the number of results
obtained between Jan 01 2012 and Dec 31 2016 depicted
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approximately 0.251 which occurs at toxin thresholds
26.6 and 26.7, whilst the maximum value for Youden’s
index is approximately 0.507, which occurs at the
toxin threshold 26.7. A cut off CT value ≤26 was
chosen as a value likely to yield EIA positivity, whilst
minimising the risk of over diagnosis (Table 2).
To investigate whether NAAT CT value correlates
with toxin EIA positivity, the following logistic regres-
sion model was used: Y = 9.50654–0.36306X (where
the response variable, Y, is the logit function of the
probability of a positive result from the toxin EIA,
and X is the NAAT CT value). The p value for the
regression coefficient for the explanatory variable is p
< 2 × 10−16, demonstrating that the CT value there is
inversely proportional to the probability of a positive
result from the toxin EIA. The model predicts the ap-
proximate probabilities of a positive EIA result as
0.904, 0.606, 0.517, 0.200 and 0.039 for the CT values
20, 25, 26, 30 and 35, respectively.
NAAT CT vs mortality
Between 2012 and 2016, 210 patients died within a month
of a C. difficile NAAT positive result, this increased to 331
after 3 months (Table 1); 805 patients did not die. A logis-
tic regression model was used to identify whether CT
value corresponds with mortality. When looking at the
number of deaths within 1 month, the following
regression model was used: Y = − 0.85203 − 0.03996X (the
response variable, Y, is the logit function of 1-month mor-
tality, and the explanatory variable, X, is the NAAT CT
value). The p value for the regression coefficient for the
explanatory variable is p = 0.0262, indicating that a low
CT value is associated with mortality. The model predicts
the approximate probabilities of death within 1 month as
0.161, 0.136, 0.114 and 0.095 for the CT values 20, 25, 30
and 35, respectively.
NAAT CT vs severity of CDI
Clinical data were obtained from 80 patients with the
lowest and 138 patients with the highest CTs. 99 out
of 138 (72%) patients with a CT value between 18
and 21 had severe/recurrent CDI. Failure of first line
treatment with metronidazole was observed in 23 out
of the 39 cases with low CT values that had been
classified as mild CDI, resulting in escalation to sec-
ond line therapy such as vancomycin, fidaxomicin or
faecal microbiota therapy. Of the 80 patients with CT
values between 35 and 37, 74 (92%) of the patients
had mild CDI with resolution of symptoms following
first line therapy of metronidazole.
Discussion
In our patient population, analysis of all C. difficile
NAAT positive stool samples between 2012 and 2016
Table 1 The number of toxin EIA samples against a selection of NAAT CT value ranges with patient mortality within 1 month and
3 months
CT Value EIA Toxin Positive a Total EIA b Mortality/month c Mortality/3 months c
18 1 (100%) 1 1 1
19 4 (80%) 5 2 2
20 32 (84%) 38 7 12
21 80 (85%) 94 17 25
22 113 (80%) 140 16 29
23 119 (72%) 166 23 31
24 106 (67%) 157 27 39
25 96 (56%) 171 21 34
26 63 (50%) 125 12 19
27 52 (37%) 139 19 34
28 24 (27%) 89 7 13
29 23 (24%) 95 10 16
30 17 (20%) 83 8 16
31–37 24 (7%) 347 41 60
All 754 (46%) 1650 210 331
18–25 551 (72%) 772 113 173
26–37 203 (23%) 878 97 158
a All samples are GDH, NAAT and toxin A and B EIA positive
b Total number of toxin A and B EIAs undertaken from GDH and NAAT positive samples including both negative and positive results for toxin A and B
c Reflects the number of patients with 1 month or 3-month mortality
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indicated that a low NAAT CT value was independently
associated with toxin EIA positivity, higher mortality
and CDI severity. We propose that a microbiological
marker cut off, based on CT value (≤26), could be used
as a predictor of poor outcome and serve as a severity
indicator to guide treatment of CDI.
In this study, regression analysis demonstrated that
low CT values were associated with toxin EIA positiv-
ity. With a CT value ≤26 we saw ≥72% toxin EIA
positivity; applying a logistic regression model we
demonstrated an association between low CT values
and toxin EIA positivity. Conversely a CT value of
≤26 would miss 28% of patients that were EIA posi-
tive. It is not surprising that a low CT value is linked
with toxin EIA positivity as previous studies have
suggested expression of toxin is associated with the
severity of CDI, and a correlation between faecal
toxin levels and C. difficile counts has been reported
in mice [12]. Dionne et al., previously identified that
amplification CT values correlate to bacterial load
[29]. They demonstrated toxin positive samples had
higher bacterial loads than toxin negative samples and
Fig. 2 ROC curve comparing NAAT CT value vs toxin EIA positivity. Note: The area under the ROC curve (AUC) was equal to AUC = 0.819. The
y-axis is the True Positive Fraction, or sensitivity, and the x-axis is the False Positive Fraction, which is equal to 1 − specificity. The True Positive
Fraction is the probability that for a fixed cut off, c, the classifier (M) gives a positive result when the true result (D) is positive, i.e. TPF(c) = P(M ≥ c|
D = Positive). In a similar fashion, the False Positive Fraction is the probability that for a fixed cut off the classifier gives a positive result when the
true result is negative, i.e. TPF(c) = P(M≥ c| D = Negative)
Table 2 Comparison of NAAT CT values (1/c) vs toxin EIA
positivity
CT value Sensitivity (TPF) Specificity FPF PPV NPV
20 0.008 0.998 0.002 0.750 0.544
21 0.050 0.992 0.008 0.844 0.554
22 0.163 0.975 0.025 0.848 0.581
23 0.314 0.944 0.056 0.826 0.621
24 0.472 0.891 0.109 0.784 0.667
25 0.613 0.834 0.166 0.756 0.719
26 0.733 0.751 0.249 0.713 0.770
27 0.820 0.682 0.318 0.684 0.818
28 0.883 0.585 0.415 0.642 0.856
29 0.915 0.507 0.493 0.610 0.876
30 0.948 0.426 0.574 0.582 0.907
35 0.995 0.076 0.924 0.475 0.944
The table shows CT values against various diagnostic measures used in the
ROC analysis including sensitivity and specificity. The area under the ROC
curve (AUC) was equal to AUC = 0.819, corresponding to a CT value of ≤26
TPF True Positive Fraction, FPF False Positive Fraction, PPV Positive Predictive
Value, NPV Negative Predictive Value
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there was a significant inverse correlation between
PCR CT values and bacterial loads [29]. In the
present study, low CT values inversely correlate to
toxin assay positivity, one could imply that CT values
of toxin B genes act as a marker of the amount of
toxin produced [12]. However, investigations seeking
to link quantitative toxin production with C. difficile
virulence have not been conclusive [12]. Further work
is warranted to explore this.
In the UK, two stage algorithms for CDI have been
adopted [4, 10]. Often a GDH test for screening is
employed followed by a toxin EIA [4, 10]. Eyre et al.,
(2017) sequenced all GDH positive patients and com-
pared the probability of faecal toxin positive and
toxin negative patients being likely sources of trans-
mission, that is, having C. difficile genetically linked
to a subsequent isolate in another patient [30]. They
concluded faecal toxin negative patients were similarly
infectious to faecal toxin positive patients; faecal toxin
status did not affect transmission rates [30]. They
concluded strategies to identify and institute infection
control measures around patients with potentially
toxigenic C. difficile without detected faecal toxin are
likely to reduce CDI incidence [30]. NAAT could be
used as a screening test as it is rapid and highly sen-
sitive to aid detection of such cases from an infection
control perspective [31]. In addition with concerns
about the lower sensitivity of toxin EIA testing in-
creased usage of NAAT in hospitals worldwide has
been seen [12]. The results in our study suggest a
NAAT CT value of ≤26 corresponds to toxin EIA
positivity. In our setting, a GDH test followed by
NAAT using the CT value as marker of EIA positivity
would seem to be sufficient to pick up the majority
of EIA positive cases. NAAT detects the DNA of the
toxin gene of C. difficile rather than the presence of
toxin in stool samples, however in our study a low
CT value shows a strong association with toxin EIA
positivity. Our finding is in line with the observations
of Jazmati et al., (2016) that free toxin detection is
associated with low CT-values [32]. As in our study
Jazmati et al., (2016) showed CT-values were signifi-
cantly lower in specimens that were positive in toxi-
genic culture (26.2 ± 4.5, n = 100 versus 30.5 ± 5.0, n =
65; p < 0.001) [32]. Senchyna et al., (2017) also found
low CT values predicted free toxin results; a CT value
of <26.35 could sensitively predict 96.0% of toxin EIA
/ PCR stool samples with a negative predictive value
of 97.1% and with a specificity of 78.0% using both
EIA toxin and cell cytotoxin assay [33]. In our study
it is important to note that the toxin EIA has a sensi-
tivity of 94.7% which could affect the CT value of
≤26 corresponding to toxin EIA positivity. One main
disadvantage of NAATs is that they do not detect the
presence of biologically active toxin in stool
specimens [15]. Toxins expressed by C. difficile are
the main virulence factor, and some feel that the
presence of toxin in stool is a positive correlation of
disease [4, 12, 15]. The significance of detecting C.
difficile in the absence of the toxins, such as in the
patient who tests positive by NAAT but negative by
toxin EIA, is unclear [15].
The majority of large studies on C. difficile diagnos-
tics show toxin EIA is the best predictor of outcome,
with NAAT tests providing no additional information
about disease severity [4, 9, 11, 13]. However, in our
study 72% (n = 99/138) patients with a CT value be-
tween 18 and 21 had severe/recurrent CDI based on
PHE guidelines for management of CDI [20]. In the
mild cases, with a CT value between 18 and 21, we
often saw treatment failure with our first line therapy
of metronidazole requiring escalation of treatment. In
contrast, 92% (n = 74/80) of the patients with a high
CT value had mild CDI and responded to treatment.
In our setting, the CT value could be used to guide
treatment of patients with CDI. It must be noted we
have only looked at a small number of patients with
either the lowest or highest CT values. Reigadas et
al., (2016) also showed patients with severe disease
had significantly lower CT-values (toxin B CT value
of <23.5) compared with patients in the other groups
[12]. In our study, we also looked at the mortality
within a month of CDI. It must be noted we have
looked at all-cause mortality and not mortality specifically
attributed to CDI. However, a significant association be-
tween low CT value and mortality was observed. Rao et al.
(2015) found that there was no correlation between ampli-
fication CT values and severe CDI or all-cause mortality,
however in our study; the mean toxin B amplification CT
value was 27.1, which was much lower than that reported
by Rao et al. (34.3) [34]. There were limitations in the
study by Rao et al., (2015) which included sampling
amounts and specimen transport. [34]
It is often difficult to distinguish between healthcare
associated diarrhoea and CDI [1]. In CDI, the spectrum
of clinical disease ranges from mild diarrhoea to toxic
megacolon, colonic perforation and death [1]. Research
suggests that both strain characteristics and the host’s
immune response influence CDI severity, recurrence risk
and mortality [1]. Jazmati et al., Reigadas et al., and
Senchyna et al., all showed a correlation between low
NAAT CT values and severity and/or patient outcome
[12, 32, 33]. To our knowledge, this is the largest study
reporting a significant association between CT values of
a NAAT C. difficile test vs toxin EIA positivity and mor-
tality. There is growing evidence that NAAT CT values
could be used to predict CDI severity, recurrence risk
and mortality.
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Conclusion
Using ROC analysis to identify a relationship between
CT value and EIA toxin positivity we were able to pre-
dict a cut off CT value threshold of ≤26 which was asso-
ciated with a high probability of EIA positivity. In
addition, we showed a low CT value was associated with
mortality within a month. Low CT values were also asso-
ciated with more severe cases of CDI in our setting. A
CT value of ≤26 could be used as an adjunct in the test-
ing algorithm for C. difficile to enable detection of toxin
EIA positive strains, as well as be used in conjunction
with clinical parameters to assess disease severity and
guide treatment of patients with CDI. However, we
recognise that more work is needed to understand the
nature of any link between low CT values and severity of
CDI. We also suggest that, since a low CT value corre-
lates with a positive toxin EIA, a CT ≤26 could in theory
be used to guide reporting and streamline the conten-
tious testing issues of CDI.
Finally, we hypothesise that increased presence of C.
difficile in the gastrointestinal tract of affected individ-
uals leads to enhanced toxin detection, resulting in lower
CT values and reflecting the phenomenon of gut dysbio-
sis that is thought to precipitate this disease.
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